Edwige Schreyer obtained a Master’s degree in Human Pathophysiology from the University of Strasbourg, France. She then followed with a PhD in Molecular and Cellular Biology at the same University specializing in castration-resistant prostate cancer. She then moved to industry in 2019 working for a biotech analytical contract research organization before joining AdipoPharma’s team in late 2020. Currently, she serves as a Senior Project Manager of the company overseeing preclinical development of the company’s lead compound for clinical testing.